UNMC commences clinical trial of remdesivir for treating COVID-19
Category: #health  By Pankaj Singh  Date: 2020-02-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

UNMC commences clinical trial of remdesivir for treating COVID-19

A controlled, randomized clinical trial to evaluate the efficacy and safety of the investigational antiviral, remdesivir, in COVID-19 patients has reportedly commenced at the University of Nebraska Medical Center (UNMC) in Omaha.

According to sources, this clinical trial is being sponsored by NIAID (National Institute of Allergy and Infectious Diseases), a division of the National Institutes of Health (NIH).

It is the first clinical study in the U.S. to determine an experimental therapy for COVID-19. The first participant to register in the clinical trial is an American who was brought to the UNMC campus after being quarantined on the Diamond Princess cruise ship that berthed in Yokohama, Japan. The person agreed to participate in the clinical study.

Presently, there are no particular treatments approved by the U.S. FDA to treat people with COVID-19. On Feb. 24, the WHO ( World Health Organization ) had recorded 77,262 confirmed COVID-19 cases and 2,595 deaths in China and 2,069 confirmed cases and 23 deaths in 29 other nations.

As per CDC (Centers for Disease Control and Prevention), there have been fourteen confirmed cases recorded in the U.S. and further 39 cases among persons deported to the U.S.

Clinical studies of remdesivir are also progressing in China. NIAID developed the present study taking those designs into account and in line with consultations convened by the WHO on the advancement of clinical trials for COVID-19 patients.

Anthony S. Fauci, M.D., the United States Coronavirus Task Force member and Director of NIAID, said that there is an urgent need for an effective and safe treatment for COVID-19. Fauci added that though remdesivir has been administered to a few COVID-19 patients, they do not possess the data indicating it could enhance clinical results.

A placebo-controlled, randomized clinical trial is the gold standard for defining experimental treatment benefit in coronavirus patients.

Source Link - https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...